The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Immunotherapy in MSI-H/dMMR mCRC: first-line options and dual checkpoint inhibition insights
Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, discussed the introduction of immunotherapy for MSI-H/dMMR metastatic colorectal cancer (mCRC). He emphasizes that immunotherapy is the best first-line treatment option and highlights the debate between using PD-L1 inhibitors alone or in combination with CTLA-4 inhibitors. Exciting new data presented at the meeting showed that the combination of nivolumab and ipilimumab is a valuable first-line treatment, suggesting that dual immune checkpoint inhibition may be more effective than using PD-L1 or PD-1 inhibitors alone. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role – 3T BioSciences; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses – Bayer; BMS; Merck Serono
